RTP Mobile Logo

In these audio proceedings from a closed Think Tank meeting in New York, New York, the invited faculty members discuss and debate current nonprotocol management of prostate cancer in addition to relevant papers and presentations emerging over the past year in this area of solid tumor oncology. This content is available in a number of formats for listening on the go with a mobile device or in the office or at home on a computer.

Listen to audio excerpts

Track 1: Intermittent versus continuous androgen deprivation in patients with hormone-sensitive metastatic prostate cancer (PC) or rising prostate-specific antigen (PSA) after local therapy — Results and implications of the international Phase III SWOG-S9346 (INT-0162) and NCIC CTG PR.7 trials
Track 2: Case discussion: A 75-year-old man with a rising PSA and a doubling time of 8 months undergoes androgen deprivation therapy (ADT)
Track 3: Mechanism of action of androgen synthesis inhibitors — abiraterone acetate and orteronel
Track 4: Mechanism of action of the novel, oral, small-molecule androgen receptor signaling inhibitor enzalutamide (MDV3100)
Track 5: Interim analysis of the Phase III COU-AA-302 study: Abiraterone acetate in patients with chemotherapy-naïve metastatic castration-resistant PC (mCRPC)
Track 6: Perspectives on the clinical use of newly approved endocrine agents in PC
Track 7: AFFIRM study results: Overall survival advantage with enzalutamide in patients with mCRPC previously treated with docetaxel
Track 8: Perspectives on sequencing enzalutamide and abiraterone acetate
Track 9: Risk of seizures with enzalutamide
Track 10: Toxicity profile of abiraterone
Track 11: Case discussion: A 67-year-old man with progressive CRPC and bone metastases receives enzalutamide on a clinical trial
Track 12: Therapeutic options for patients with mCRPC whose disease progresses on enzalutamide
Track 13: Updated activity and tolerability results from a Phase II study of orteronel without prednisone for men with nonmetastatic CRPC and rising PSA levels
Track 14: Case discussion: A 68-year-old man with nonmetastatic CRPC treated with orteronel on a clinical trial
Track 15: Complications of long-term steroid administration
Track 16: Viewpoints on the inclusion and dosing of steroids with lyase inhibitor therapy
Track 17: ALSYMPCA: Updated analysis from a Phase III trial of radium-223 chloride for patients with CRPC and bone metastases
Track 18: Rationale for using radium-223
Track 19: Antitumor and bone-protective activity of radium-223
Track 20: Potential integration of radium-223 into the treatment algorithm for PC
Track 21: Case discussion: An 83-year-old man with symptomatic, metastatic PC and a T12 epidural spinal cord compression achieves improved pain control with radium-223
Track 22: Use of zoledronic acid or denosumab in combination with radiopharmaceutical therapy
Track 23: Perspectives on the future nonprotocol role of radium-223
Track 24: Correlation of immune parameters and overall survival among patients receiving sipuleucel-T
Track 25: Development of the immunotherapeutic agent sipuleucel-T in mCRPC
Track 26: Interdisciplinary critique of sipuleucel-T as immunotherapy for CRPC
Track 27: Case discussion: A 59-year-old man with asymptomatic CRPC, bone metastases and a rising PSA receives treatment with sipuleucel-T
Track 28: Viewpoints on the use of sipuleucel-T for asymptomatic CRPC
Track 29: Critical appraisal of the Phase III IMPACT trial results evaluating sipuleucel-T for mCRPC
Track 30: Expanding treatment options for mCRPC
Track 31: Monitoring patient response after completion of sipuleucel-T therapy
Track 32: Case discussion: A 70-year-old man with mCRPC refractory to docetaxel and endocrine therapies experiences a rapid PSA decline with cabazitaxel treatment on the Phase III PROSELICA trial
Track 33: Approach to the use of preemptive growth factors with cabazitaxel
Track 34: Use of cabazitaxel for patients with docetaxel-refractory mCRPC
Track 35: Analysis of the TROPIC trial (cabazitaxel/prednisone versus mitoxantrone/prednisone): PSA decline as a surrogate for overall survival in patients with mCRPC that progressed on first-line chemotherapy
Track 36: Key ongoing Phase III trials of cabazitaxel in mCRPC: FIRSTANA — first-line docetaxel versus cabazitaxel — and PROSELICA — evaluation of 2 different doses of cabazitaxel in patients who previously received docetaxel
Track 37: Treatment options for patients with symptomatic mCRPC progressing on docetaxel
Track 38: Treatment algorithms for patients with asymptomatic and symptomatic mCRPC
Track 39: Potential incorporation of next-generation endocrine agents — abiraterone and enzalutamide — into earlier lines of treatment
Track 40: Benefits and risks of long-term endocrine therapy in PC
Track 41: Mechanism of action of the novel antisense agent custirsen (OGX-011)
Track 42: Results from the Phase II CUOG trial P-06c: Custirsen in combination with docetaxel or mitoxantrone as second-line therapy for patients with mCRPC progressing after first-line docetaxel
Track 43: Ongoing Phase III trials evaluating custirsen in combination with taxane-based chemotherapy versus taxane-based therapy alone as first- or second-line therapy for patients with mCRPC
 
FACULTY:
 
Tomasz M Beer, MD
Grover C Bagby Endowed
Chair for Prostate Cancer Research
Professor of Medicine
Hematology and Medical Oncology
Deputy Director
OHSU Knight Cancer Institute Portland, Oregon
 
Robert Dreicer, MD, MS
Chairman, Department of
Solid Tumor Oncology
Taussig Cancer Institute
Cleveland Clinic
Professor of Medicine
Cleveland Clinic Lerner
College of Medicine
Cleveland, Ohio
 
Mario A Eisenberger, MD
R Dale Hughes Professor of
Oncology and Urology
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins
Baltimore, Maryland
 
William K Oh, MD
Chief, Division of Hematology
and Medical Oncology
Professor of Medicine and Urology
Ezra M Greenspan, MD
Professor in Clinical Cancer Therapeutics
Mount Sinai School of Medicine
Associate Director of Clinical Research
The Tisch Cancer Institute
New York, New York
 
Daniel P Petrylak, MD
Professor of Medicine
Program Director,
Genitourinary Oncology
Co-Director,
Signal Transduction Program
Yale Comprehensive Cancer Center
New Haven, Connecticut
 
A Oliver Sartor, MD
Medical Director
Tulane Cancer Center
Laborde Professor of Cancer Research
Professor of Medicine and Urology
Tulane Medical School
New Orleans, Louisiana
 
Susan F Slovin, MD, PhD
Associate Attending Physician
Genitourinary Oncology Service
Sidney Kimmel Center for Prostate
and Urology Cancers
Memorial Sloan-Kettering Cancer Center
Associate Professor of Medicine
Weill-Cornell Medical College
New York, New York
 
Matthew R Smith, MD, PhD
Professor of Medicine
Harvard Medical School Director
Genitourinary Malignancies Program
Massachusetts General Hospital
Boston, Massachusetts
 
MODERATOR:
 
Neil Love, MD
Research To Practice
Miami, Florida